Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEK | Q02763 | 6/20 | 0.73 |
| ▸ | FLT1 | P17948 | 2/20 | 0.60 |
| ▸ | KDR | P35968 | 2/20 | 0.60 |
| ▸ | MAP4K4 | O95819 | 7/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 2/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4476973 | 0.91 | TEK (0.73) | TEKFLT1KDRMAP4K4BRAF | |
| SCHEMBL4464925 | 0.88 | TEK (0.70) | TEKFLT1KDRMAP4K4BRAF | |
| SCHEMBL4467818 | 0.86 | TEK (0.83) | TEKFLT1KDRMAP4K4RAB9A | |
| SCHEMBL4485440 | 0.85 | TEK (0.70) | TEKFLT1KDRMAP4K4LCK | |
| SCHEMBL4796059 | 0.84 | TEK (1.00) | TEKFLT1KDRMAP4K4BRAF | |
| SCHEMBL4802186 | 0.84 | TEK (0.86) | TEKFLT1KDRMAP4K4BRAF | |
| SCHEMBL4480247 | 0.84 | TEK (0.85) | TEKFLT1KDRMAP4K4BRAF | |
| SCHEMBL4801489 | 0.83 | TEK (0.83) | TEKFLT1KDRBRAF | |
| SCHEMBL4471994 | 0.81 | TEK (0.85) | TEKFLT1KDRNPC1RAB9A | |
| SCHEMBL4484707 | 0.80 | TEK (0.83) | TEKFLT1KDRNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7476677-B2 | Substituted thieno- and thiazolo- [2,3-d]pyrimidines and [2,3-c]pyridines as inhibitors of Tie2 | ASTRAZENECA AB (SE) | 2009-01-13 | — | — | US | claimed |
| EP-1716155-B1 | SUBSTITUTED THIENO- AND THIAZOLO[2,3-D]PYRIMIDINES AND [2,3-C]PYRIDINES AS INHIBITORS OF TIE2 | ASTRAZENECA AB (SE) | 2008-02-27 | — | — | EP | claimed |
| US-20070135455-A1 | Substituted thieno- and thiazolo- [2,3-d]pyrimidines and [2,3-c]pyridines as inhibitors of tie2 | ASTRA ZENECA AB (SE) | 2007-06-14 | — | — | US | claimed |
| US-7476677-B2 | Substituted thieno- and thiazolo- [2,3-d]pyrimidines and [2,3-c]pyridines as inhibitors of Tie2 | ASTRAZENECA AB (SE) | 2009-01-13 | — | — | US | disclosed |
| EP-1716155-B1 | SUBSTITUTED THIENO- AND THIAZOLO[2,3-D]PYRIMIDINES AND [2,3-C]PYRIDINES AS INHIBITORS OF TIE2 | ASTRAZENECA AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| US-20070135455-A1 | Substituted thieno- and thiazolo- [2,3-d]pyrimidines and [2,3-c]pyridines as inhibitors of tie2 | ASTRA ZENECA AB (SE) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135455-A1 | Substituted thieno- and thiazolo- [2,3-d]pyrimidines and [2,3-c]pyridines as inhibitors of tie2 | TIE1, TEK, TEKT1 | TEK 2/4885FLT1 6/4885KDR 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.